防感散联合咳喘贴治疗小儿反复上呼吸道感染缓解期肺脾气虚型46例临床观察

linical observation on 46 cases of recurrent upper respiratory tract infections in remission stage in children with qi asthenia in lung and spleen type treated by Fanggan San(防感散)combined with Kechuan Tie(咳喘贴)

目的观察防感散联合咳喘贴治疗小儿反复上呼吸道感染缓解期肺脾气虚型的临床疗效。方法选取2019年3—6月衢州市中医医院儿科就诊的反复上呼吸道感染缓解期肺脾气虚型患儿92例,按照随机数字表法分为对照组和治疗组,各46例,对照组予匹多莫德口服液口服治疗,治疗组予防感散联合咳喘贴治疗,均于夏季初伏时治疗,连续治疗6周后统计临床疗效。结果治疗组总有效率为93.48%(43/46),明显高于对照组的78.26%(36/46),2组比较,差异有统计学意义(P<0.05)。治疗前2组的发病次数和平均病程比较,差异无统计学意义(P>0.05),具有可比性;治疗后2组的发病次数和平均病程均较同组治疗前明显降低(P<0.05),且治疗组降低更显著,差异均有统计学意义(P<0.05)。治疗前2组的分泌性免疫球蛋白A(sIgA)异常例数比较,差异无统计学意义(P>0.05),具有可比性;治疗后治疗组的sIgA改善率为78.57%(22/28),明显高于对照组的53.33%(16/30),2组比较,差异有统计学意义(P<0.05)。治疗期间治疗组仅有2例患儿出现敷药处皮肤轻微灼烧感,可耐受,且不影响治疗;对照组未出现明显不良反应。结论防感散联合咳喘贴治疗小儿反复上呼吸道感染缓解期肺脾气虚型疗效确切,可显著减少发病次数,缩短病程,改善sIgA指标,且安全性高,值得临床推广应用。

Objective To observe the clinical efficacy of Fanggan San(防感散)combined with Kechuan Tie(咳喘贴)in the treatment of recurrent upper respiratory tract infections(RURTIs)in remission stage in children with qi asthenia in lung and spleen type.Methods From March to June in 2019,92 cases of RURTIs in remission stage with qi asthenia in lung and spleen type consulted in pediatrics department of Quzhou Hospital of TCM were divided into control group and treatment group according to random number table method,with 46 cases in each group.The control group was given oral administration of pidotmod oral solution,while the treatment group was given Fanggan San combined with Kechuan Tie.The 2 groups were both treated at first period of dog-days in summer,and we kept statistics about the clinical efficacy after 6 weeks of continuous treatment.Results The total effective rate of the treatment group was 93.48%(43/46),which was significantly higher than 78.26%(36/46)of the control group,and the difference was statistically significant between the 2 groups(P<0.05).Before treatment,the difference was not statistically significant in onset frequency and average course of disease between the 2 groups(P>0.05),indicating comparability.After treatment,onset frequency and average course of disease of the 2 groups significantly decreased compared with those in the same group before treatment(P<0.05),moreover,the treatment group decreased more significantly,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the number of abnormal cases of secretory immunoglobulin A(sIgA)between the 2 groups(P>0.05),indicating comparability.After treatment,the improvement rate of sIgA in the treatment group was 78.57%(22/28),which was significantly higher than 53.33%(16/30)in the control group,and the difference was statistically significant between the 2 groups(P<0.05).During the treatment,only 2 children patients in the treatment group had a slight skin burning sensation at the dressing site,which was tolerant and did not affect the treatment.There were no significant adverse reactions in the control group.Conclusion It has definite efficacy,can significantly reduce onset frequency,shorten the course of disease,and improve sIgA with high safety to use Fanggan San combined with Kechuan Tie in the treatment of RURTIs in children in remission stage with qi asthenia in lung and spleen type,which is worthy of clinical promotion and application.